Anupam Das
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anupam Das has a total of 328 co-authors. Here are the top co-authors by number of shared publications:
Piyush Kumar
Department of Dermatology, Madhubani Medical College, Madhubani, Bihar, India
38 shared publications- Abheek Sil
Department of Dermatology, Venereology, and Leprosy, PKG Medical College and Hospital , Kolkata
17 shared publications Indrashis Podder
Department of Dermatology, College of Medicine and Sagore Dutta Hospital, Kamarhati, Kolkata, India
17 shared publicationsDipti Das
Department of Dermatology, Medical College and Hospital, Kolkata, West Bengal, India
14 shared publicationsAnupama Ghosh
Department of Dermatology, CGHS, Kolkata, West Bengal, India
12 shared publicationsKaushik Shome
Department of Dermatology, Burdwan Medical College and Hospital, Burdwan, West Bengal, India
10 shared publications
Latest Publications
- 30 October 2026
- Published by Wolters Kluwer Health in Indian Journal of Dermatology
Obesity and Skin: A Review Focusing on Cell Signalling Proteins
Obesity is a heritable trait, influenced by environmental, genetic, and metabolic factors. It is a risk factor for a multitude of conditions like hypertension, type II diabetes mellitus, non-alcoholic fatty liver disease, certain malignancies and dermatological conditions like psoriasis, atopic dermatitis, rosacea, malignant melanoma, acne vulgaris, and many more. This review is an attempt to outline the signalling proteins behind the development of obesity and their pathogenetic and therapeutic implications in the field of dermatology.
- 30 October 2026
- Published by Wolters Kluwer Health in Indian Journal of Dermatology
Obesity and Skin: A Review Focusing on Cell Signalling Proteins
Obesity is a heritable trait, influenced by environmental, genetic, and metabolic factors. It is a risk factor for a multitude of conditions like hypertension, type II diabetes mellitus, non-alcoholic fatty liver disease, certain malignancies and dermatological conditions like psoriasis, atopic dermatitis, rosacea, malignant melanoma, acne vulgaris, and many more. This review is an attempt to outline the signalling proteins behind the development of obesity and their pathogenetic and therapeutic implications in the field of dermatology.
- 28 August 2026
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
Effectiveness, safety and tolerability of ozenoxacin 2% lotion vs. clindamycin 1% lotion in mild-to-moderate truncal acne: an open-label randomized controlled clinical trial
Background: Truncal acne is a frequently encountered but relatively understudied manifestation of acne vulgaris and is often associated with significant physical discomfort and psychosocial impact. Topical clindamycin has been used extensively in mild-to-moderate acne; however, there are concerns regarding antimicrobial resistance, which has prompted interest in alternative topical agents. Ozenoxacin, a nonfluorinated quinolone, offers broad-spectrum antibacterial activity with minimal systemic absorption. Objectives: To compare the effectiveness, safety and tolerability of ozenoxacin 2% lotion with clindamycin 1% lotion in patients with mild-to-moderate truncal acne. Methods: This institution-based, open-label, randomized controlled trial (registered with the Clinical Trials Registry of India: CTRI/2025/02/080133) included 78 patients aged 18–35 years with mild-to-moderate truncal acne. Participants were randomized to receive either ozenoxacin 2% lotion or clindamycin 1% lotion applied twice daily for 12 weeks. Both groups received adapalene 0.1% gel for once-daily application at bedtime. Clinical efficacy and quality of life were assessed using total, inflammatory and noninflammatory lesion counts, and the Investigator Global Assessment, Cardiff Acne Disability Index and Dermatology Life Quality Index scores. Safety was evaluated through adverse event monitoring. Results: Thirty-five patients in the ozenoxacin group and 34 in the clindamycin group completed the study. Both groups demonstrated statistically significant improvement from baseline in all efficacy parameters at 12 weeks (P < 0.05). Intergroup comparisons showed no statistically significant differences across clinical or quality-of-life outcomes. Both treatments were well tolerated, with only mild and transient adverse effects reported. Conclusions: Ozenoxacin demonstrated comparable efficacy and tolerability to clindamycin when used in combination with adapalene in truncal acne.
- 28 August 2026
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
Effectiveness, safety and tolerability of ozenoxacin 2% lotion vs. clindamycin 1% lotion in mild-to-moderate truncal acne: an open-label randomized controlled clinical trial
Background: Truncal acne is a frequently encountered but relatively understudied manifestation of acne vulgaris and is often associated with significant physical discomfort and psychosocial impact. Topical clindamycin has been used extensively in mild-to-moderate acne; however, there are concerns regarding antimicrobial resistance, which has prompted interest in alternative topical agents. Ozenoxacin, a nonfluorinated quinolone, offers broad-spectrum antibacterial activity with minimal systemic absorption. Objectives: To compare the effectiveness, safety and tolerability of ozenoxacin 2% lotion with clindamycin 1% lotion in patients with mild-to-moderate truncal acne. Methods: This institution-based, open-label, randomized controlled trial (registered with the Clinical Trials Registry of India: CTRI/2025/02/080133) included 78 patients aged 18–35 years with mild-to-moderate truncal acne. Participants were randomized to receive either ozenoxacin 2% lotion or clindamycin 1% lotion applied twice daily for 12 weeks. Both groups received adapalene 0.1% gel for once-daily application at bedtime. Clinical efficacy and quality of life were assessed using total, inflammatory and noninflammatory lesion counts, and the Investigator Global Assessment, Cardiff Acne Disability Index and Dermatology Life Quality Index scores. Safety was evaluated through adverse event monitoring. Results: Thirty-five patients in the ozenoxacin group and 34 in the clindamycin group completed the study. Both groups demonstrated statistically significant improvement from baseline in all efficacy parameters at 12 weeks (P < 0.05). Intergroup comparisons showed no statistically significant differences across clinical or quality-of-life outcomes. Both treatments were well tolerated, with only mild and transient adverse effects reported. Conclusions: Ozenoxacin demonstrated comparable efficacy and tolerability to clindamycin when used in combination with adapalene in truncal acne.
- Open Access
- 12 June 2026
- Published by Wiley in International Journal of Dermatology
Expert Consensus on the Management of Hyperpigmentation Disorders in India: A Modified Delphi Study by the Pigmentary Disorders Society
Hyperpigmentation disorders are prevalent in individuals with skin of color and are associated with considerable psychosocial impact. Clinical heterogeneity, chronic relapsing course, and limited evidence often result in suboptimal outcomes. This consensus aimed to develop evidence‐informed, expert consensus recommendations for the diagnosis and management of common hyperpigmentation disorders in the Indian context. A modified Delphi study was conducted by Indian experts of the Pigmentary Disorders Society (PDS) between August 2025 and January 2026. Twelve dermatologists with expertize in pigmentary disorders participated. An exploratory round identified four priority conditions: melasma, acquired dermal macular hyperpigmentation, post‐inflammatory hyperpigmentation, and periorbital hyperpigmentation. A broad literature review informed the development of the statements. Two rounds of anonymous voting using a 5‐point Likert scale and a virtual meeting were undertaken. Consensus was predefined as high (≥ 75%), moderate (55%–74%), or low (< 55%). In Round 1, 34 statements were evaluated; 21 achieved high consensus, 9 moderate, and 4 low. Following the virtual discussion and refinement, 11 revised statements were revoted on in Round 2, resulting in 32 final high‐consensus statements. Key recommendations emphasized proactive prevention and relapse minimization in Fitzpatrick skin types III–VI, the use of dermoscopy and Wood's lamp for aiding diagnosis, and the use of histopathology when indicated. Overall, the consensus favored combination approaches targeting melanogenesis, inflammation, and photoprotection. The panel also outlined preferred topical, oral, and procedural options based on existing evidence and clinical experience. Overall, this consensus provides contextualized guidance for major hyperpigmentation disorders, emphasizing individualized and multimodal management. image
- 12 June 2026
- Published by Wiley in International Journal of Dermatology
Open AccessExpert Consensus on the Management of Hyperpigmentation Disorders in India: A Modified Delphi Study by the Pigmentary Disorders Society
Hyperpigmentation disorders are prevalent in individuals with skin of color and are associated with considerable psychosocial impact. Clinical heterogeneity, chronic relapsing course, and limited evidence often result in suboptimal outcomes. This consensus aimed to develop evidence‐informed, expert consensus recommendations for the diagnosis and management of common hyperpigmentation disorders in the Indian context. A modified Delphi study was conducted by Indian experts of the Pigmentary Disorders Society (PDS) between August 2025 and January 2026. Twelve dermatologists with expertize in pigmentary disorders participated. An exploratory round identified four priority conditions: melasma, acquired dermal macular hyperpigmentation, post‐inflammatory hyperpigmentation, and periorbital hyperpigmentation. A broad literature review informed the development of the statements. Two rounds of anonymous voting using a 5‐point Likert scale and a virtual meeting were undertaken. Consensus was predefined as high (≥ 75%), moderate (55%–74%), or low (< 55%). In Round 1, 34 statements were evaluated; 21 achieved high consensus, 9 moderate, and 4 low. Following the virtual discussion and refinement, 11 revised statements were revoted on in Round 2, resulting in 32 final high‐consensus statements. Key recommendations emphasized proactive prevention and relapse minimization in Fitzpatrick skin types III–VI, the use of dermoscopy and Wood's lamp for aiding diagnosis, and the use of histopathology when indicated. Overall, the consensus favored combination approaches targeting melanogenesis, inflammation, and photoprotection. The panel also outlined preferred topical, oral, and procedural options based on existing evidence and clinical experience. Overall, this consensus provides contextualized guidance for major hyperpigmentation disorders, emphasizing individualized and multimodal management. image
- Open Access
- 14 May 2026
- Published by Scientific Scholar in Journal of Clinical Imaging Science
- Vol. 6
Acquired lymphangiectasia with hemangiomatous transformation in a child: A report
Acquired lymphangiectasia with hemangiomatous transformation in a child: A report
- 14 May 2026
- Published by Scientific Scholar in Journal of Clinical Imaging Science
- Vol. 6
Open AccessAcquired lymphangiectasia with hemangiomatous transformation in a child: A report
Acquired lymphangiectasia with hemangiomatous transformation in a child: A report
- Open Access
- 1 May 2026
- Published by Wolters Kluwer Health in Pigment International
- Vol. 13 (2) , 73-74
Editorial Priorities for Pigment International: Building on a Strong Foundation
Was not provided for this article.
- 1 May 2026
- Published by Wolters Kluwer Health in Pigment International
- Vol. 13 (2) , 73-74
Open AccessEditorial Priorities for Pigment International: Building on a Strong Foundation
Was not provided for this article.
- 23 January 2026
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 51 (5) , 805-813
The changing face of dermatophytosis: from common skin disease to emerging resistant epidemic
Dermatophytosis is a commonly encountered superficial fungal infection with an affinity for keratin-rich structures, such as skin, hair and nails. The recently emerging recalcitrant dermatophytosis is a recurrent, relapsing, chronic or persistent disease, which has a significant impact on the social, emotional and financial aspects of a patient’s life. Trichophyton indotineae, a newly identified species, has become resistant to conventional therapies, unlike its predecessor. This review highlights the shift of this commonly encountered skin disease from an easily manageable clinical entity to an emerging resistant epidemic. We also discuss why dermatophytosis is being labelled as a ‘designated fungal threat’.
- 23 January 2026
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 51 (5) , 805-813
The changing face of dermatophytosis: from common skin disease to emerging resistant epidemic
Dermatophytosis is a commonly encountered superficial fungal infection with an affinity for keratin-rich structures, such as skin, hair and nails. The recently emerging recalcitrant dermatophytosis is a recurrent, relapsing, chronic or persistent disease, which has a significant impact on the social, emotional and financial aspects of a patient’s life. Trichophyton indotineae, a newly identified species, has become resistant to conventional therapies, unlike its predecessor. This review highlights the shift of this commonly encountered skin disease from an easily manageable clinical entity to an emerging resistant epidemic. We also discuss why dermatophytosis is being labelled as a ‘designated fungal threat’.
- 7 January 2026
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 51 (5) , 789-804
Post-kala-azar dermal leishmaniasis: a global overview
Post-kala-azar dermal leishmaniasis (PKDL) is a chronic dermal sequela in apparently cured patients with visceral leishmaniasis (VL). It presents with either macular or polymorphic forms, and poses a major epidemiological challenge in South Asia, particularly in India, Bangladesh and Nepal. Although nonfatal, PKDL acts as a reservoir for Leishmania donovani, thereby sustaining transmission in the postelimination phase of VL. Potential risk factors for PKDL include a history of VL, immunosuppression, host genetics and malnutrition. The disease burden is further complicated by poor health-seeking behaviour and stigma associated with dermal lesions, leading to diagnostic delays and under-reporting. PKDL is associated with a mixed T helper 1/2 profile, translating into a mixed anti-inflammatory/regulatory and proinflammatory milieu. This is coupled with prominent infiltration of immune cells into lesional sites, including macrophages, lymphocytes and neutrophils, which cause localized immune alteration. The diagnosis of PKDL is challenging in macular cases due to their low parasite burden and overlapping symptoms with other hypopigmentary disorders, but molecular tools now offer improved sensitivity and even have field-level applicability. In terms of therapeutics, the management of PKDL is hindered by the need for prolonged treatment, chances of relapse, emerging drug resistance and noncompliance. Overall, the integration of molecular diagnostics, immunological insights and community-based treatment strategies are essential to eliminate PKDL and sustain efforts to eliminate kala-azar.
- 7 January 2026
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 51 (5) , 789-804
Post-kala-azar dermal leishmaniasis: a global overview
Post-kala-azar dermal leishmaniasis (PKDL) is a chronic dermal sequela in apparently cured patients with visceral leishmaniasis (VL). It presents with either macular or polymorphic forms, and poses a major epidemiological challenge in South Asia, particularly in India, Bangladesh and Nepal. Although nonfatal, PKDL acts as a reservoir for Leishmania donovani, thereby sustaining transmission in the postelimination phase of VL. Potential risk factors for PKDL include a history of VL, immunosuppression, host genetics and malnutrition. The disease burden is further complicated by poor health-seeking behaviour and stigma associated with dermal lesions, leading to diagnostic delays and under-reporting. PKDL is associated with a mixed T helper 1/2 profile, translating into a mixed anti-inflammatory/regulatory and proinflammatory milieu. This is coupled with prominent infiltration of immune cells into lesional sites, including macrophages, lymphocytes and neutrophils, which cause localized immune alteration. The diagnosis of PKDL is challenging in macular cases due to their low parasite burden and overlapping symptoms with other hypopigmentary disorders, but molecular tools now offer improved sensitivity and even have field-level applicability. In terms of therapeutics, the management of PKDL is hindered by the need for prolonged treatment, chances of relapse, emerging drug resistance and noncompliance. Overall, the integration of molecular diagnostics, immunological insights and community-based treatment strategies are essential to eliminate PKDL and sustain efforts to eliminate kala-azar.
- 3 January 2026
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 51 (5) , 779-788
Childhood leprosy: a current appraisal
Leprosy is a disease of great antiquity that affects individuals of all ages and backgrounds. Despite consolidated global control efforts, the disease has remained endemic in many regional pockets. In this regard, particular epidemiological attention is paid to childhood infection as it highlights disease transmission. Children are especially susceptible to leprosy due to their immature immunity and potential intrafamilial contact sources. This provides an opportunity to detect the index case, usually within the family. Leprosy in children has the potential to cause progressive physical deformity, with consequent psychosocial impacts on both the child and the caregiver family. This narrative review focuses on leprosy in the paediatric population, encompassing epidemiological, clinical, diagnostic and therapeutic aspects.
- 3 January 2026
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 51 (5) , 779-788
Childhood leprosy: a current appraisal
Leprosy is a disease of great antiquity that affects individuals of all ages and backgrounds. Despite consolidated global control efforts, the disease has remained endemic in many regional pockets. In this regard, particular epidemiological attention is paid to childhood infection as it highlights disease transmission. Children are especially susceptible to leprosy due to their immature immunity and potential intrafamilial contact sources. This provides an opportunity to detect the index case, usually within the family. Leprosy in children has the potential to cause progressive physical deformity, with consequent psychosocial impacts on both the child and the caregiver family. This narrative review focuses on leprosy in the paediatric population, encompassing epidemiological, clinical, diagnostic and therapeutic aspects.
- 30 December 2025
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 51 (5) , 687-689
Skin neglected tropical diseases
- 30 December 2025
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 51 (5) , 687-689
Skin neglected tropical diseases